Ray Dalio Exelixis, Inc. Transaction History

Bridgewater Associates, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $259,137 - $301,229	17,322 New	17,322 $277,000
Q2 2022 Aug 11, 2022	BUY	$17.44 - $23.16 $86,519 - $114,896	4,961 Added 29.45%	21,808 $454,000
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $286,904 - $381,921	16,847 New	16,847 $382,000
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $274,182 - $355,595	-16,821 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $301,936 - $429,944	16,821 New	16,821 $306,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.